UK medicines – Is the Northern Ireland Protocol now unsustainable?
von Dr Paul England
The UK and the Trans-Pacific Partnership – Could patent conflicts ruin the deal?
Available in English and Japanese
von Dr Paul England
The EU torpedoes itself in cross-border patent disputes
von Dr Paul England
Edison Open House Global Healthcare 2021 – key takeaways from our panel
von mehreren Autoren
Will the UK government's COVID-19 dosing regime gamble pay off?
von Alison Dennis und Justyna Ostrowska
One Nucleus Genesis Digital 2020 – Key takeaways from our cell and gene therapy panel session
von Adrian Toutoungi
8+2+1 plus what? How UK data and market exclusivity rights will be affected from 1 January 2021
von Alison Dennis und Dr Paul England
Biologics and biosimilars litigation update
von Matthew Royle, Ph.D. und Dr. Nora E. Wessendorf, LL.M. (Washington)
SPC for ezetimibe/simvastatin considered invalid in preliminary relief proceedings
Targeted treatments – Part 3: the power of orphan drug protection
von Dr Paul England
German Federal Court of Justice invalidates Truvada SPC
Targeted treatments – Part 1: Targeted treatments: patents for particular populations
von Dr Paul England